Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York. Show more

Location: 19 Vestry Street, New York, NY, 10013, United States | Website: https://brightmindsbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

824.1M

52 Wk Range

$23.18 - $123.75

Previous Close

$83.00

Open

$83.31

Volume

82,733

Day Range

$81.72 - $86.50

Enterprise Value

739.9M

Cash

82.91M

Avg Qtr Burn

-2.173M

Insider Ownership

11.47%

Institutional Own.

63.44%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BMB-101 Details Epilepsy, Developmental and Epileptic Encephalopathy (DEE), Absence Seizures (AS)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMB-101 Details Prader-Willi Syndrome (PWS)	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMB-105 Details Prader-Willi Syndrome (PWS)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.